SCHEMBL550208

SCHEMBL550208

Fc1cc2c(cc1F)NCC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
AR P10275 3/20 0.40
PARP1 P09874 1/20 0.37
PARP10 Q53GL7 1/20 0.37
P4HB P07237 1/20 0.36
GFER P55789 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GRM5 P41594 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
KDM4E B2RXH2 2/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
THRB P10828 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28923502 0.98 DRD2 (0.45) DRD2DRD4MAPTALDH1A1AR
Hydrochloric Acid SCHEMBL30142473 0.98 DRD2 (0.45) DRD2DRD4MAPTALDH1A1AR
SCHEMBL2217869 0.86 MAPT (0.45) DRD2DRD4MAPTALDH1A1AR
SCHEMBL17937412 0.85 MAPT (0.40) DRD2DRD4MAPTALDH1A1AR
SCHEMBL23384713 0.83 ALDH1A1 (0.53) DRD2DRD4MAPTALDH1A1AR
SCHEMBL30964480 0.83 HTR2A (0.47) DRD2DRD4MAPTALDH1A1AR
SCHEMBL5827521 0.83 HTR2A (0.47) DRD2DRD4MAPTALDH1A1AR
SCHEMBL30727376 0.83 ALDH1A1 (0.53) DRD2DRD4MAPTALDH1A1AR
SCHEMBL6101285 0.83 ALDH1A1 (0.49) DRD2DRD4MAPTALDH1A1AR
SCHEMBL8527251 0.83 DRD2 (0.41) DRD2DRD4MAPTALDH1A1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4605089-A1 COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K Mekanistic Therapeutics LLC (US) 2025-08-27 EP disclosed
US-20250019380-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2025-01-16 US disclosed
CN-118791417-A Pink back pteridonic acid derivative, preparation method and application thereof 安徽工业大学 2024-10-18 CN disclosed
EP-3858811-B1 N-AROMATIC AMIDES COMPOUND AND PREPARATION METHOD AND USE THEREOF SHENZHEN EDK PHARMACEUTICAL TECH CO LTD (CN) 2024-07-17 EP disclosed
WO-2024133499-A1 GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES RHEINISCHE-FRIEDRICH-WILHELMS-UNIVERSITÄT BONN (DE) 2024-06-27 WO disclosed
EP-4370124-A1 PI3Ka INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2024-05-22 EP disclosed
WO-2024086296-A1 COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K MEKANISTIC THERAPEUTICS LLC (US) 2024-04-25 WO disclosed
US-20230382870-A1 N-AROMATIC AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF SHENZHEN EDK PHARMACEUTICAL TECH CO LTD (CN) 2023-11-30 US disclosed
US-20230382870-A1 N-AROMATIC AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF SHENZHEN EDK PHARMACEUTICAL TECH CO LTD (CN) 2023-11-30 US disclosed
US-20230382870-A1 N-AROMATIC AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF SHENZHEN EDK PHARMACEUTICAL TECH CO LTD (CN) 2023-11-30 US disclosed
US-20110195954-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-11 US disclosed
US-20110021500-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-27 US disclosed
US-20110021500-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-27 US disclosed
US-20110021500-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-27 US disclosed
WO-2011001114-A1 NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS SANOFI-AVENTIS (FR) 2011-01-06 WO disclosed
EP-2251338-A2 Organic compounds Boehringer Ingelheim International GmbH (DE) 2010-11-17 EP disclosed
EP-2251339-A2 COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2010-11-17 EP disclosed
EP-2251339-A2 COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2010-11-17 EP disclosed
WO-2009065920-A2 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-28 WO disclosed
WO-2009065919-A2 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021500-A1 NOVEL COMPOUNDS CALCRL, CALCR, CALCA DRD2 640/4885DRD4 694/4885MAPT 797/4885
US-20250019380-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF PIK3CA, PIK3CB, PIK3CD DRD2 4864/4885DRD4 4854/4885MAPT 3881/4885
US-20230382870-A1 N-AROMATIC AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF H1-3, H1-0, NAT1 DRD2 291/4885DRD4 379/4885MAPT 1983/4885
US-20110195954-A1 NOVEL COMPOUNDS CALCRL, CALCR, CALCA DRD2 738/4885DRD4 784/4885MAPT 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.